Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

Ferry A.L.M. Eskens, Herlinde Dumez, Ronald Hoekstra, Anton Perschl, C. Brindley, Sebastian Böttcher, Wim Wynendaele, Joachim Drevs, Jaap Verweij, A.T. van Oosterom

European Journal of Cancer · 2003 · 223 citations · 16 references

Concepts

References

16